
NYSEHealthcareMedical - Care Facilities
أحدث البيانات المتاحة
179.25 US$
+2.23 US$ · +1.26%
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
الإغلاق السابق
179.25 US$
+2.23 US$ · +1.26%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
نطاق اليوم
السعر الحالي 179.25 US$
نطاق 52 أسبوعًا
السعر الحالي 179.25 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
54
قيمة عادلة
المشاعر
60
مختلط
المخاطر
20
مخاطر منخفضة
الزخم
72
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
نطاق اليوم
السعر الحالي 179.25 US$
نطاق 52 أسبوعًا
السعر الحالي 179.25 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 13.64 مليار USD | 12.82 مليار USD | 12.14 مليار USD | 11.61 مليار USD | 11.62 مليار USD |
| تكلفة البضاعة المباعة | 9.96 مليار USD | 8.6 مليار USD | 8.32 مليار USD | 8.21 مليار USD | 7.97 مليار USD |
| الربح الإجمالي | 3.68 مليار USD | 4.22 مليار USD | 3.82 مليار USD | 3.4 مليار USD | 3.65 مليار USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 1.67 مليار USD | 1.54 مليار USD | 1.47 مليار USD | 1.36 مليار USD | 1.2 مليار USD |
| نفقات التشغيل | 1.67 مليار USD | 2.13 مليار USD | 2.22 مليار USD | 2.06 مليار USD | 1.85 مليار USD |
| مصاريف الفوائد | 549.67 مليون USD | 470.47 مليون USD | 398.55 مليون USD | 357.02 مليون USD | 285.25 مليون USD |
| الاستهلاك والإطفاء | 715.35 مليون USD | 723.86 مليون USD | 745.44 مليون USD | 732.6 مليون USD | 680.62 مليون USD |
| الدخل التشغيلي | 2.01 مليار USD | 2.09 مليار USD | 1.6 مليار USD | 1.34 مليار USD | 1.8 مليار USD |
| صافي الدخل | 746.8 مليون USD | 936.34 مليون USD | 691.54 مليون USD | 560.4 مليون USD | 978.45 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
235.67 US$
ارتفاع محتمل بنسبة 31.48%| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 9 سبتمبر 2013 | 2:1 | — | — |
تقسيم الأسهم | 16 يونيو 2004 | 3:2 | — | — |
تقسيم الأسهم | 21 أكتوبر 1997 | 5:3 | — | — |
ساري 9 سبتمبر 2013
2:1
ساري 16 يونيو 2004
3:2
ساري 21 أكتوبر 1997
5:3
صناديق متداولة تفصح عن تعرضها لهذا السهم.
State Street SPDR S&P 500 ETF1557.T11.58 مليار0.01%129.35 ترليون JPY0.09%122,850 JP¥+0.12%
Invesco S&P 500 Equal Weight ETFRSP192.16 مليون0.20%97.78 مليار USD0.20%213.04 US$+0.55%
Vanguard Morningstar Total Stock Market ETFVTI179.76 مليون0.01%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard S&P 500 ETFVOO150 مليون0.01%1.8 ترليون USD0.03%715.59 US$+0.61%
Vanguard Morningstar Small-Cap ETFVB130.08 مليون0.07%185.3 مليار USD0.03%289.48 US$+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR82.56 مليون0.12%68.2 مليار USD0.05%234.43 US$+0.22%
iShares Core S&P 500 ETFIVV79.63 مليون0.01%896.44 مليار USD0.03%781.97 US$+0.60%
State Street SPDR S&P 500 ETFSPY73.11 مليون0.01%817.2 مليار USD0.09%778.57 US$+0.60%
State Street SPDR S&P 500 ETF1557.T
Invesco S&P 500 Equal Weight ETFRSP
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPYالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.